Does minimal residual disease (MRD) predict relapse in children with advance B-NHL treated with chemoimmunotherapy: a children's oncology report

被引：0
|
作者：
Shiramizu, B. [1 ]
Goldman, S. [2 ]
Smith, L. [3 ]
Harrison, L. [4 ]
Van de Ven, C. [4 ]
Gross, T. [5 ]
Sanger, W. [6 ]
Perkins, S. [7 ]
Cairo, M. [4 ,8 ,9 ,10 ,11 ]
机构：
[1] Univ Hawaii, Honolulu, HI 96822 USA
[2] Med City Childrens Hosp, Dallas, TX USA
[3] Childrens Oncol Grp, Ctr Data, Omaha, NE USA
[4] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA
[5] Ohio State Univ, Nationwide Childrens Hosp, Columbus, OH 43210 USA
[6] Univ Nebraska, Omaha, NE 68182 USA
[7] Univ Utah, Salt Lake City, UT USA
[8] New York Med Coll, Dept Med, Valhalla, NY 10595 USA
[9] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA
[10] New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA
[11] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 159卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
101
引用
收藏
页码：53 / 53
页数：1
相关论文
共 50 条
  • [41] ISOLATED MYC REARRANGEMENT BY CYTOGENETICS/FISH IN CHILDREN AND ADOLESCENTS (C&A) WITH STAGE III/IV B-NHL BM+ AND/OR CNS+ MAY HAVE AN IMPROVED OUTCOMES FOLLOWING IMMUNOCHEMOTHERAPY: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
    Nelson, M.
    Goldman, S.
    Harrison, L.
    Cairo, M. S.
    Sanger, W.
    ANNALS OF ONCOLOGY, 2011, 22 : 175 - 175
  • [42] Potential utility of minimal residual disease (MRD) to identify relapse in pediatric and young adult (AYA) B-cell acute lymphoblastic leukemia (B-ALL) patients treated with tisagenlecleucel
    Pulsipher, Michael A.
    Han, Xia
    Quigley, Maire
    Kari, Gabor
    Rives, Susana
    Laetsch, Theodore W.
    Myers, Gary D.
    Hiramatsu, Hidefumi
    Yanik, Gregory A.
    Qayed, Muna
    Driscoll, Timothy
    Boyer, Michael W.
    Stefanski, Heather
    Buchner, Jochen
    Baruchel, Andre
    Bader, Peter
    Yi, Lan
    Kalfoglou, Creton
    Robins, Harlan
    Yusko, Erik
    Gorgun, Gullu
    Bleickardt, Eric
    Wong, Stephane
    Grupp, Stephan A.
    CANCER RESEARCH, 2019, 79 (13)
  • [43] Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C plus A) with stage III/IV (Group B) and BM plus /CNS plus (Group C) mature B-NHL: A Children's Oncology Group report.
    Cairo, M. S.
    Lynch, J. C.
    Harrison, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T. G.
    Sanger, W.
    Goldman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] A novel approach for minimal residual disease detection in childhood T-Cell lymphoblastic lymphoma (T-LL): A children's oncology group report
    Custan-Smith, Elaine
    Abromowitz, Minnie
    Sandlund, John T.
    Campana, Dario
    BLOOD, 2007, 110 (11) : 1042A - 1043A
  • [45] A CUSTOM QUANTITATIVE REAL TIME PCR MINIMAL RESIDUAL DISEASE (MRD) ASSAY PREDICTS OUTCOME IN MLL-REARRANGED (MLL-R) INFANT ALL: A CHILDREN'S ONCOLOGY GROUP STUDY
    Schafer, Eric S.
    Murphy, Kathleen M.
    Burns, Kathleen
    McIntyre, Emily
    Borowitz, Michael J.
    Hunger, Stephen P.
    Wood, Brent
    Carroll, Andrew
    Heerema, Nyla
    Harvey, Richard
    Willman, Cheryl L.
    Dreyer, Zoann
    Devidas, Meenakshi
    Brown, Patrick
    PEDIATRIC BLOOD & CANCER, 2009, 52 (06) : 694 - 695
  • [46] Minimal Disseminated Disease in Childhood T-Cell Lymphoblastic Lymphoma: A Report From the Children's Oncology Group
    Coustan-Smith, Elaine
    Sandlund, John T.
    Perkins, Sherrie L.
    Chen, Helen
    Chang, Myron
    Abromowitch, Minnie
    Campana, Dario
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) : 3533 - 3539
  • [47] WT1 Expression at Diagnosis Does Not Predict Survival in Pediatric AML: A Report From the Children's Oncology Group
    Noronha, Suzie A.
    Farrar, Jason E.
    Alonzo, Todd A.
    Gerbing, Robert B.
    Lacayo, Norman J.
    Dahl, Gary V.
    Ravindranath, Yaddanapudi
    Arceci, Robert J.
    Loeb, David M.
    PEDIATRIC BLOOD & CANCER, 2009, 53 (06) : 1136 - 1139
  • [48] Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) Treated in the AIEOP-BFM ALL 2000 Study.
    Biondi, Andrea
    Schrauder, Andre
    Valsecchi, Maria Grazia
    Bartram, Claus R.
    Mann, Georg
    De Rossi, Giulio
    Moericke, Anja
    Parasole, Rosanna
    Harbott, Jochen
    Messina, Chiara
    Rizzari, C.
    Masera, Giuseppe
    Schrappe, Martin
    BLOOD, 2008, 112 (11) : 537 - 538
  • [49] Measurable Residual Disease Detection in B-Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method
    Borowitz, Michael J.
    Wood, Brent L.
    Keeney, Michael
    Hedley, Benjamin D.
    CURRENT PROTOCOLS, 2022, 2 (03):
  • [50] Detection of Minimal Residual Disease in Down Syndrome-AML by Error-Corrected Sequencing: A Children's Oncology Group Study
    Tong, R. S.
    Young, A. L.
    Wong, W. H.
    Hitzler, J.
    Berman, J. N.
    Druley, T. E.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S117 - S117
12345